Considering the substantial glycosylation observed on cell-surface PD-L1 in gastric cancer cells, the generation of antibodies against glycosylated PD-L1 or the use of pharmacologic approaches for PD-L1 deglycosylation could hold the potential to enhance antibody binding. This evidence concerns the gene CD274 and gastric cancer.